Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 12,25 € (+20,22 %). Medianen er 12,25 € (+20,22 %).
| Køb |
5 |
| Behold |
5 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Neogen rises after Piper Sandler upgrade and price-target increase
Neogen's stock climbed about 3% in premarket trading after Piper Sandler raised its rating from "Neutral" to "Overweight" and lifted the price target from $13 to $14. The bank cited improved operational performance, accelerated growth in the food-safety segment, rising adjusted EBITDA margins, positive free cash flow and restored product availability. In the most recent fiscal fourth quarter, Neogen beat expectations on both adjusted EPS ($0.09) and revenue ($225.3 million) and issued a 2027 revenue forecast of $880–885 million, above analysts' estimates. » Mere på de.investing.com
Neogen reaches 52-week high of $11.45 after strong quarterly results
Neogen shares rose to a new 52-week high of $11.45 and are currently trading at $11.46, giving the company a market capitalization of about $2.48 billion. Over the past year the stock gained roughly 100–144%, and year-to-date it is up about 34%. For the fourth quarter of fiscal 2026, Neogen reported adjusted earnings of $0.09 per share and revenue of $225.3 million, both above expectations, with organic growth of 4.3% (5.8% in the food safety segment). However, an InvestingPro valuation suggests the stock may be overvalued relative to its fair-value estimate. » Mere på de.investing.com
Neogen stock: investment from ten years ago would be about 54% less valuable
On 18 June 2016 Neogen stock traded at USD 19.54; a USD 100 investment would have bought 5.118 shares at that time. At the last closing price of USD 8.93 that investment would be worth only USD 45.71, a decline of 54.29%. Neogen is most recently valued at around USD 2.02 billion; stock splits and dividends are not taken into account. » Mere på finanzen.net
Neogen reports Q3 fiscal 2026 margin expansion and Animal Safety supply‑chain headwinds
Neogen posted 4% core growth in Food Safety and expanded adjusted EBITDA margins to 22.8% driven by cost control and a 9% sequential cut in adjusted operating expenses. Animal Safety revenue fell 8.7% on a core basis due to third‑party supplier transitions, raw‑material shortages and documentation issues rather than demand weakness, with resolution expected beyond Q4. Management plans a unified global commercial model, centralized supply chain and AI logistics, expects Petrifilm manufacturing to transition by November 2026, anticipates stronger free cash flow in fiscal 2027 and aims to reduce net debt/adjusted EBITDA below 3x after a genomics divestiture. » Mere på finance.yahoo.com
Neogen raises full-year guidance; food safety growth offsets decline in animal health
Neogen reported Q3 FY26 revenue of $211.2 million and adjusted EPS of $0.09, both above expectations. The food safety segment grew organically by 4.0%, while the animal health segment shrank organically by 8.7%. Adjusted EBITDA was $48.2 million with a margin of 22.8%, supported by cost discipline. Management raised the full-year revenue guidance to $857–$860 million and still expects about $175 million of adjusted EBITDA; supply-chain issues in animal health are likely to persist into the fourth quarter. A planned divestiture of the genomics business (approx. $160 million) and the conversion of Petrifilm manufacturing by November 2027 are intended to improve the balance sheet and margins. » Mere på de.investing.com
Virksomhedstal
| (EUR) | august 2026 | YoY |
|---|---|---|
| Omsætning | 191,78 mio. | 7,18 % |
| Bruttofortjeneste | 90,81 mio. | 11,79 % |
| Nettoresultat | -10,24 mio. | 132,95 % |
| EBITDA | 24,1 mio. | 68,45 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 2,22 mia. € |
Antal aktier | 218,31 mio. |
Højeste/laveste i 52 uger | 12,94 € - 4,87 € |
| Udbytte | Nej |
Beta | 1,86 |
P/E (PE Ratio) | -44,35 |
PEG (PEG Ratio) | 0,03 |
K/I (PB Ratio) | 1,17 |
P/S (PS Ratio) | 2,77 |
Virksomhedsprofil
Neogen Corporation og dets datterselskaber udvikler, fremstiller og markedsfører forskellige produkter til fødevare- og dyresikkerhed over hele verden. Virksomheden opererer gennem to segmenter, Food Safety og Animal Safety. Food Safety-segmentet tilbyder diagnostiske testkits og relaterede produkter til at påvise farlige og utilsigtede stoffer i fødevarer og dyrefoder, herunder fødevarebårne patogener, fordærvelsesorganismer, naturlige toksiner, fødevareallergener, genetiske modifikationer, biprodukter fra drøvtyggere, artsbestemmelse af kød, lægemiddelrester, pesticidrester og generelle hygiejneproblemer; samt AccuPoint Advanced, en hurtig sanitetstest for adenosintriphosphat, et kemisk stof, der findes i levende celler. Dette segment tilbyder sine produkter primært til fødevare- og foderforarbejdere; kornproducenter og -forarbejdere; producenter af kiks, kiks, slik, is og andre forarbejdede fødevarer; kød- og fjerkræforarbejdere, forarbejdere af skaldyr og fisk, frugt- og grøntsagsproducenter samt mejerier; laboratorier; og producenter af lægemidler, kosmetik, veterinærvacciner og nutraceutiske produkter. Animal Safety-segmentet leverer veterinærinstrumenter, lægemidler, vacciner, lokalbehandlingsmidler, diagnostiske produkter, rodenticider, rengøringsmidler, desinfektionsmidler, insekticider og genomiske testydelser til markedet for dyresikkerhed. Segmentet tilbyder forskellige produkter til forskere til påvisning af biologisk aktive stoffer. Dets immunoassay-testkits til narkotikapåvisning anvendes til at påvise misbrugte og terapeutiske lægemidler hos landbrugs- og væddeløbsdyr, påvisning af lægemiddelrester i kød og kødprodukter samt rettsmedicinske toksikologiske narkotikascreeningsapplikationer til mennesker. Desuden anvendes segmentets produkter til at opretholde hygiejniske forhold og begrænse de potentielle farer fra bakterier, svampe og virus. Virksomheden sælger sine produkter direkte samt gennem distributører og detailkæder. Neogen Corporation blev stiftet i 1981 og har hovedkvarter i Lansing, Michigan.
| Navn | Neogen Co. |
| CEO | Mikhael Nassif |
| Hjemsted | Lansing,
mi USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 23.08.1989 |
| Medarbejdere | 2.636 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | NEOG |
Frankfurt | NG2.F |
Düsseldorf | NG2.DU |